Optherion’s intellectual property is based on genetic discoveries linking certain genes to AMD and orphan renal diseases strongly influenced by components of the alternative complement system. Sequenom is currently marketing a predictive test based on Optherion technology that identifies patients who are predisposed to late stage age-related macular degeneration.
Meanwhile, Baxter, which acquired the rights to Optherion’s therapeutic program via an asset purchase and license agreement, is exploring recombinant and plasma-derived complement Factor H as a therapeutic targeting the treatment of AMD.
New Haven, CT
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.